Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary objective: To demonstrate that QVA149 (110/50 μg q.d.) is superior compared to placebo on peak inspiratory capacity (IC) after 21 days of treatment in patients with moderate to severe COPD. Co-primary objective: To evaluate whether QVA149 is superior to placebo with respect to average physical activity level as defined by average daily activity-related energy consumption [Kcal/day].
Critère d'inclusion
- Chronic Obstructive Pulmonary Disease (COPD)